Genomate Health is a Cambridge, MA–based medtech company founded in 2022 by physician‑scientist Istvan Petak, MD, PhD. Its flagship product, Genomate™, is described as the world’s first clinically validated universal computational reasoning model for precision oncology that analyzes patients’ unique combinations of genetic alterations and biomarkers to predict responses to multiple targeted therapies. The company intends to present results as comprehensive, data-backed reports to guide oncologists and patients toward the most suitable treatments. With this raise Genomate plans to scale operations, engage in pilot programs, and collaborate with additional partners to accelerate deployment. Management also plans to pursue FDA clearance for the platform to enable broader clinical access. Genomate cites more than two decades of supporting research and references the SHIVA01 randomized clinical trial as part of its scientific foundation. The company has gained external recognition, including placement on a Forbes list, participation in the White House CancerX initiative, and graduation from the Mayo Clinic Platform_Accelerate program.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2024